|1.||Jones, Ronald N: 22 articles (07/2015 - 06/2010)|
|2.||Sader, Helio S: 19 articles (07/2015 - 06/2010)|
|3.||Flamm, Robert K: 12 articles (07/2015 - 09/2012)|
|4.||Rybak, Michael J: 11 articles (12/2015 - 11/2009)|
|5.||Farrell, David J: 10 articles (07/2015 - 04/2011)|
|6.||Friedland, H David: 7 articles (01/2015 - 09/2010)|
|7.||Nicolau, David P: 7 articles (12/2014 - 07/2011)|
|8.||Biek, Donald: 7 articles (12/2012 - 09/2008)|
|9.||File, Thomas M: 6 articles (02/2015 - 12/2010)|
|10.||Ge, Yigong: 6 articles (07/2011 - 10/2007)|
09/01/2008 - "Ceftaroline was very potent against bacteria found in community- and hospital-acquired infections, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, and common Enterobacteriaceae spp."
03/01/2014 - "Although a non-inferiority design was used for these clinical trials, some data suggest a superior efficacy of ceftaroline, with earlier clinical response and higher cure rate in infections caused by S. "
02/01/2009 - "Phase II and III studies have shown ceftaroline to be an effective and well-tolerated treatment for complicated skin and skin-structure infections compared with standard therapy. "
03/01/2015 - "Importantly, these data also suggest that ceftaroline can be effective in patients with serious invasive MRSA infections who have failed other therapies. "
07/01/2011 - "Ceftaroline was effective against the 4 isolates tested and may provide a clinical option for the treatment of DNS MRSA infections."
12/01/2009 - "We assessed the in vitro and in vivo efficacy of the novel parenteral broad-spectrum cephalosporin ceftaroline against Enterococcus faecalis in time-kill experiments and in a rabbit endocarditis model with simulated human dosing. "
07/01/2014 - "Salvage treatment of methicillin-resistant staphylococcal endocarditis with ceftaroline: a multicentre observational study."
03/01/2014 - "Ceftaroline deserves major attention as an alternative choice in difficult-to-treat MRSA endocarditis."
03/01/2014 - "Ceftaroline for the treatment of prosthetic valve endocarditis due to methicillin-resistant Staphylococcus aureus."
11/01/2013 - "Here we review the outcomes of 31 patients with MRSAB treated with ceftaroline, including 9 patients with endocarditis. "
02/01/2013 - "In most patients, ceftaroline was effective for treatment of MRSA bacteremia and other severe MRSA infections. "
12/01/2014 - "There is little data on clinical success of ceftaroline in patients with bacteremia or endocarditis other than what has been published in a small series of case reports. "
10/01/2014 - "Ceftaroline plus daptomycin may be an option to hasten clearance of refractory staphylococcal bacteremia. "
10/01/2014 - "After daptomycin plus ceftaroline was started, the median time to bacteremia clearance was 2 days (range, 1-6 days). "
10/01/2014 - "All 26 cases from the 10 medical centers in which ceftaroline plus daptomycin was used for treatment of documented refractory staphylococcal bacteremia from March 2011 to November 2012 were included. "
09/01/2012 - "In summary, ceftaroline resistance surveillance (Assessing Worldwide Antimicrobial Resistance Evaluation [AWARE] Program) in the United States (2008-2010) documented in vitro sustained potency and spectrum against Gram-positive and Gram-negative pathogens known to cause community-acquired bacterial pneumonia."
06/01/2012 - "Activity of ceftaroline against serotyped Streptococcus pneumoniae isolates from Europe and South Africa associated with community-acquired bacterial pneumonia (2007-08)."
01/01/2012 - "Clinical evaluation of the role of ceftaroline in the management of community acquired bacterial pneumonia."
04/01/2010 - "Ceftaroline is a renally excreted broad-spectrum cephalosporin that is clinically effective for the treatment of complicated skin and skin structure infections and community-acquired bacterial pneumonia, and it has distinctive activity against some difficult-to-treat multidrug-resistant gram-positive organisms."
04/01/2015 - "In this study, the probability of pharmacokinetic/pharmacodynamic target attainment (PTA) of ceftaroline against clinical isolates causing community-acquired bacterial pneumonia (CABP) and complicated skin and skin-structure infection (cSSSI) in Europe was evaluated. "
08/01/2010 - "Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis."
04/01/2013 - "Little data exist regarding ceftaroline use in osteomyelitis."
08/01/2010 - "The present study supports ceftaroline as a promising therapeutic option for the treatment of severe MRSA infections, including osteomyelitis."
08/01/2013 - "A 90-year-old female was given ceftaroline for treatment of a pneumonia complicated by methicillin-resistant Staphylococcus aureus bacteraemia and possible vertebral osteomyelitis. "
04/01/2013 - "No data are available supporting clinical effectiveness for ceftaroline or tigecycline in the setting of osteomyelitis. "
|9.||Anti-Bacterial Agents (Antibiotics)
|10.||CAP18 lipopolysaccharide-binding protein (Bac4)
|2.||Renal Dialysis (Hemodialysis)